Globin Solutions, Inc. is a biotechnology company that leverages heme-based solutions and protein engineering to develop innovative antidotal therapies aimed at treating human poisonings. The company's research focuses on the chemistry and biology of heme proteins, particularly in understanding the molecular mechanisms of carbon monoxide (CO) poisoning and the development of heme-based antidotes. Their lead compound, recombinant neuroglobin, is a significant advancement in this area, showcasing the potential of globin chemistry in therapeutic applications.

The team at Globin Solutions comprises experts with extensive backgrounds in medicine, biochemistry, and biotechnology. Key personnel include Dr. Jason J. Rose, who has a strong focus on CO poisoning mechanisms, and Dr. Jesus Tejero, whose research emphasizes the interactions of nitrite with heme proteins. The company also collaborates with regulatory and development experts to ensure compliance and efficacy in their therapeutic offerings. Overall, Globin Solutions is positioned at the forefront of biotechnological innovation, aiming to address critical health challenges through its specialized research in heme-based therapies.

United States

Globin Solutions, Inc. is a pre-clinical stage biopharmaceutical company that is committed to researching and developing a rapidly acting antidote for carbon monoxide poisoning, the most common human poisoning. Globin intends to aggressively develop its lead compound through preclinical testing with the goal to pursue regulatory clearance for clinical testing. Globin plans to partner with experts in globin chemistry and protein engineering through sponsored research agreements with the University of Pittsburgh to further develop their pipeline of agents for CO poisoning and other indications.

Globin Solutions

Company Details